Want to see MRK full AI Analyst Report?
MRK Stock Chart & Stats
$131.07
$0.59(0.45%)
At close: 4:00 PM EDT
$131.07
$0.59(0.45%)
Day’s Range― - ―
52-Week Range$77.53 - $135.05
Previous CloseN/A
Volume6.15M
Average Volume (3M)10.42M
Market Cap
$321.97B
Enterprise Value$340.75K
Total Cash (Recent Filing)$5.70B
Total Debt (Recent Filing)$49.12B
Price to Earnings (P/E)37.0
Beta0.32
Next Earnings
Aug 04, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend Yield2.59%
Share Statistics
EPS (TTM)3.56
Shares Outstanding2,469,824,500
10 Day Avg. Volume8,822,586
30 Day Avg. Volume10,418,009
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)5.01
Price to Sales (P/S)4.06
P/FCF Ratio21.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$136.94Price Target Upside4.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)2.77
Revenue Forecast (FY)$66.81B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowConsistent, sizable FCF (~$14.1B TTM, +~14%) supplies durable internal funding for R&D, launches, dividends and buybacks. High cash generation improves capital allocation optionality, supports long-term pipeline investment and cushions the business against cyclical revenue or earnings variability.
High And Sustainable MarginsHistorically high gross margins and a ~28% operating margin indicate structural pricing power and manufacturing scale. Durable margins provide funding for late‑stage development, commercialization and marketing, and create a buffer versus reimbursement pressure that supports long‑term profitability.
Oncology Leadership & Pipeline MomentumKEYTRUDA’s ongoing commercial momentum (Q1 $8.0B, +8% YoY) plus multiple approvals and priority reviews demonstrate durable oncology franchise strength. Continued label expansion, earlier‑line uptake and pipeline catalysts offer lasting revenue upside and diversification beyond legacy products.
Bears Say
Elevated Financial LeverageDebt-to-equity near ~1.07 TTM signals meaningful reliance on debt financing. Higher leverage reduces financial flexibility for opportunistic M&A or higher buybacks if earnings weaken, increases interest expense sensitivity and narrows the cushion against future operational or reimbursement shocks.
Earnings Volatility From Large One-time ChargesVery large, nonrecurring charges (e.g., $9B Cidara charge and an expected ~$5.8B one‑time R&D hit from Terns) materially distort GAAP results and tax rates. Such sizable one‑offs make earnings less predictable, complicate capital allocation and obscure baseline profitability trends.
Product Concentration & Demand HeadwindsA 22% YoY decline in a major vaccine (GARDASIL) highlights exposure to geographic demand swings and procurement timing. Coupled with reimbursement and seasonality hits on other products, this concentration risk can pressure revenue stability and complicate multi‑year forecasting.
Merck & Company News
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $77.53 and its highest was $135.05 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $321.97B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Aug 04, 2026 which is in 3 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Apr 30, 2026. The company reported -$1.28 earnings per share for the quarter, beating the consensus estimate of -$1.474 by $0.194.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.85 which represents an annual dividend yield of 2.59%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is -0.27.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,469,824,500 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of -$1.28 in its last earnings report, beating expectations of -$1.474. Following the earnings report the stock price went down -1.595%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$136.94 (4.48% Upside)
$136.94 (4.48% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 90%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.52%
12-Months-Change
Fundamentals
Return on Equity
2.59%
Trailing 12-Months
Asset Growth
11.78%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. (MRK) is a global, research-driven biopharmaceutical company that discovers, develops, manufactures, and commercializes human health prescription medicines and vaccines, as well as animal health products. The company’s portfolio spans oncology, vaccines, infectious diseases, cardiometabolic disease, and other therapeutic areas, and it sells its products worldwide through a combination of direct operations and third-party distributors.
MRK Company Deck
MRK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call mixed strong commercial and pipeline execution with near-term financial and clinical headwinds. Merck reported solid Q1 revenue growth (+5% YoY; $16.3B), robust KEYTRUDA momentum (+8%, $8.0B), notable product and regulatory milestones (IDVYNSO approval, priority reviews for I-DXd and multiple WELIREG filings), accelerating new-product launches and AI partnerships, and raised/narrowed 2026 guidance. Offsetting these positives were a very large one-time $9B Cidara charge that drove a GAAP loss and distorted tax rate, an expected one-time R&D impact from the proposed Terns deal (~$5.8B), meaningful declines in GARDASIL (-22%), a failed LITESPARK-012 readout, and several near-term reimbursement/seasonality headwinds for specific products (ENFLONSIA, OHTUVAYRE). Overall the company emphasized long-term pipeline value and raised guidance despite near-term charges and select clinical setbacks.View all MRK earnings summariesMRK Sales Breakdown
89.43% Pharmaceutical
9.77% Animal Health
0.79% Other
MRK Stock 12 Month Forecast
Average Price Target
$136.94
▲(4.48% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
21.78% Mutual Funds
2.97% Other Institutional Investors
50.41% Public Companies and Individual Investors